Neutrophil and platelet activation in equine recurrent airway obstruction is associated with increased neutrophil CD13 expression, but not platelet CD41/61 and CD62P or neutrophil-platelet aggregate formation.

This study explores the relationship between neutrophil and platelet activation in horses with recurrent airway obstruction (RAO), finding that the increased expression of CD13 in neutrophils could serve as a valuable indicator of the disease’s progression.

Understanding the Research

The research was conducted to understand whether changes in activation marker expressions and the formation of heterotypic aggregates in neutrophils and platelets can indicate increased functional responsiveness in horses suffering from recurrent airway obstruction (RAO). RAO is a condition prevalent in mature horses where the airways become blocked intermittently, leading to inflammation of the neutrophils.

• Neutrophils and platelets are types of blood cells that play a major role in the body’s effort to heal wounds and fight infection.
• CD13, CD41/61, and CD62P are cellular markers present on the surfaces of activated neutrophils and platelets.
• A heterotypic aggregate refers to a combination of different cell types. In this study, the authors refer to the combination of neutrophils and platelets triggered by their activation.

Key Findings

The study found that activating neutrophils and platelets led to a significant increase in the neutrophil-platelet aggregates, portrayal of the interaction between these cell types.

• After antigen challenge, horses with RAO experienced a significant increase in CD13 positive neutrophils at intervals of 10 and 24 hours.
• Moreover, a substantial rise in the mean fluorescence intensity was observed after 10 hours, highlighting the activation level of the respective samples.
• The progression was also witnessed in terms of increased mean platelet side scatter and thrombin-stimulated platelet adhesion after 24 hours.

Implications of the Study

The findings suggest that the enhanced expression of CD13 on neutrophils could potentially be used as a reliable marker for determining neutrophil activation, both in vitro and in vivo. This increased expression aligns with the pathophysiological condition of RAO in horses, hence could be used to track the progress of the disease.

However, despite evidence of platelet activation in horses’ blood circulation, researchers couldn’t detect any change in the expression of platelet activation markers nor any signal of heterotypic aggregate formation. This suggests the need for a more thorough understanding of the pathology underlying RAO and the role of different cellular components in it.